Cargando…

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada

Objective: The objective of this study was to evaluate epidemiological trends of co-use patterns of amphetamine-type stimulants and opioids and the impact of co-use patterns on Opioid Agonist Treatment (OAT) retention in Ontario, Canada. The secondary objective was to assess geographical variation i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morin, Kristen A., Vojtesek, Frank, Acharya, Shreedhar, Marsh, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721960/ https://www.ncbi.nlm.nih.gov/pubmed/34987430 http://dx.doi.org/10.3389/fpsyt.2021.782066

Ejemplares similares

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study
por: Morin, Kristen A, et al.
Publicado: (2022)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

Association of prescribed oral stimulants on cocaine use among patients enrolled in opioid agonist treatment: A retrospective longitudinal cohort study
por: Tatangelo, Mark, et al.
Publicado: (2022)

The opioid crisis: past, present and future policy climate in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2017)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
por: Morin, Kristen A., et al.
Publicado: (2020)

A retrospective cohort study evaluating correlates of deep tissue infections among patients enrolled in opioid agonist treatment using administrative data in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population
por: Thurn, Daniela, et al.
Publicado: (2017)

Psychosocial Interventions for Amphetamine Type Stimulant Use Disorder: An Overview of Systematic Reviews
por: Tran, Mai Thi Ngoc, et al.
Publicado: (2021)

Amphetamine-Related Emergency Department Visits in Ontario, Canada, 2003-2020
por: Crispo, James A.G., et al.
Publicado: (2023)

Prevalence and Correlates of Active Amphetamine-Type Stimulant Use Among Female Sex Workers in Malaysia
por: Pedersen, Courtney J., et al.
Publicado: (2022)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
por: Kouyoumdjian, Fiona G., et al.
Publicado: (2018)

Association between childhood trauma, intimate partner violence, and perceived parental competence among women abusing amphetamine-type stimulant
por: Wahab, Suzaily, et al.
Publicado: (2023)

Antipsychotics for Amphetamine Psychosis. A Systematic Review
por: Fluyau, Dimy, et al.
Publicado: (2019)

Functional Genomic Analysis of Amphetamine Sensitivity in Drosophila
por: Karam, Caline S., et al.
Publicado: (2022)

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors
por: Shen, Qianwei, et al.
Publicado: (2017)

Dextroamphetamine-Amphetamine Augmentation in the Treatment of Treatment-Resistant Depression
por: Small, Tyler M, et al.
Publicado: (2022)

Effects of Lisdexamfetamine, a Prodrug of D-Amphetamine, on Locomotion, Spatial Cognitive Processing and Neurochemical Profiles in Rats: A Comparison With Immediate-Release Amphetamine
por: Jian-min, Chen, et al.
Publicado: (2022)

Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study
por: von Bernuth, Kira, et al.
Publicado: (2020)

The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Measuring the Burden of Opioid-related Mortality in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Changes in Children and Youth’s Mental Health Presentations during COVID-19: A Study of Primary Care Practices in Northern Ontario, Canada
por: Daneshmand, Roya, et al.
Publicado: (2023)

Erratum to: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019
por: Camden, Andi, et al.
Publicado: (2021)

Availability of opioid agonist treatment and critical incidents in Forensic Clinics for Dependency Diseases in Germany
por: Reiners, Sven, et al.
Publicado: (2022)

Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation
por: Schmitz, Joy M., et al.
Publicado: (2012)

Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2022)

Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse
por: Strickland, Justin C., et al.
Publicado: (2022)

Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the ‘other epidemic’
por: Eibl, Joseph K., et al.
Publicado: (2016)

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis
por: Bodkin, Claire, et al.
Publicado: (2021)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

The four-factor personality model and its qualitative correlates among opioid agonist therapy clients
por: Mahu, Ioan T., et al.
Publicado: (2023)

The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons—Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids
por: Buadze, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fafc33jg5t7g5cushk3fa95q3j